semaglutide chronic kidney disease stage 3 dosing High-Dose (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial Semaglutide in patients with overweight

Weeks 3-6 reveal steady fat loss as your body burns stored energy at a higher rate

Understanding potential adverse effects helps patients recognise what is normal and when to seek medical advice

2025;14(4):e00346

Rybelsus (oral tablet): approved for type 2 diabetes, and cardiovascular outcome evidence continues to expand with trials like SOUL

Future research must address the gaps in biomarkers, subphenotype-specific mechanisms, and the integration of ferroptosis-targeted therapies into standard care

This combination of proper injection technique, genetic personalization, and consistent, affordable medication access creates conditions for sustainable weight loss outcomes